Valneva SE (NASDAQ:VALN) Short Interest Update

by · The Cerbat Gem

Valneva SE (NASDAQ:VALN – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 14,500 shares, a decline of 69.9% from the October 31st total of 48,200 shares. Based on an average trading volume of 20,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.0% of the shares of the company are short sold.

Valneva Trading Up 2.3 %

NASDAQ VALN traded up $0.09 during trading on Friday, hitting $4.05. 24,890 shares of the company’s stock traded hands, compared to its average volume of 12,719. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 12-month low of $3.91 and a 12-month high of $11.96. The business has a 50 day moving average of $5.49 and a 200-day moving average of $6.85.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

View Our Latest Stock Report on Valneva

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its holdings in Valneva SE (NASDAQ:VALN – Free Report) by 33.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Read More